Heart failure (HF) is a common, lethal, disabling, and expensive disorder. Its prevalence in industrialized nations has reached epidemic proportions and continues to rise. Despite significant therapeutic advances, the prognosis for patients who are admitted to the hospital with HF remains poor, with a 5-year mortality of ≈50%, which is worse than...
Skeletal myoblasts

by guest on July 30, 2017 http://circres.ahajournals.org/ Downloaded from

within a year, this therapy had been applied in patients.4 In the
care expenditures.2

per year ≈ 6 million persons, kills >300
States, HF affects
the first cell therapy for heart disease was performed) to 2012.

Illustrated is the number

Figure 1.

Use of various types of stem cell therapies in patients with cardiovascular disease. Illustrated is the number of patients treated with 6 major types of cells from 2000 (when the first cell therapy for heart disease was performed) to 2012.

that for patients with breast or colon cancer.4 In the United
States, HF affects ≈6 million persons, kills >300,000 people
per year, and is directly responsible for >$40 billion in health-care expenditures.3

Although current therapeutic approaches to HF improve
symptoms and prolong life, they are palliative in the sense that they do not address the fundamental problem of the loss of
cardiac tissue. It is for this reason that stem cells have sparked
intense interest. Stem cell–based therapies have the potential
to dramatically transform the treatment and prognosis of HF by
achieving what would have been unthinkable only a few
years ago—myocardial regeneration. For the first time since
cardiac transplantation, the goal is not damage control but
damage elimination, that is, removal of the underlying cause
of HF. It is the curative potential of this new therapy that
explains why translational efforts have proceeded at lightning
speed (Figure 1). The first study of bone marrow cells in ex-
perimental myocardial infarction (MI) was published in 20013;
within a year, this therapy had been applied in patients.4 In the
setting of HF, it took only 3 years from the first use of stem
cells (skeletal myoblasts) in an animal model5 to the first use
of these cells in humans.6 Few ideas in medicine have been
translated from the experimental laboratory to the clinical
arena faster than the use of stem cells in heart disease.

During the past 15 years, numerous preclinical and clinical
studies have been performed that support the ability of various
stem cell populations to improve cardiac function and attenu-
ate adverse left ventricular (LV) remodeling in both ischemic
and nonischemic cardiomyopathy. Despite this rapid progress,
however, many fundamental issues remain to be resolved and,
to date, no cell therapy has been conclusively shown to be
effective in patients with HF. The purpose of this article is to
critically review the large body of work performed with re-
spect to the use of stem/progenitor cells in HF, both at the
experimental and clinical levels, and to discuss current contro-
versies, unresolved issues, challenges, and future directions.
This review focuses specifically on chronic HF; studies of
stem cells in acute MI, refractory angina, and other conditions
not relevant to chronic HF are not discussed.

Stem Cell Types Investigated Heretofore in HF

Stem cells are undifferentiated, self-renewing cells that pos-
sess a multilineage differentiation potential. As illustrated in
Figure 2, various types of stem cells have been considered for
the treatment of HF. The preclinical and clinical studies that
have assessed the use of stem cells in chronic HF are summa-
rized in Tables 1 and 2, respectively.

Embryonic Stem Cells

Embryonic stem cells (ESCs) are pluripotent cells harvested
from the inner cell mass of preimplantation-stage blastocysts.69
When cultured as 3-dimensional cystic aggregates (embryoid
bodies), both mouse and human ESCs have the capacity to
differentiate into cells of all 3 germ layers, namely, ectoderm,
endoderm, and mesoderm (including cardiomyocytes).70,71

Human ESC–derived cardiomyocytes, which can be isolated
from embryoid bodies by either mechanical dissection or
enzymatic methods,72 exhibit adult cardiomyocyte morphol-
ogy with properly organized sarcomeric proteins and express
cardiac-specific transcription factors such as NK2 homeobox
5 (Nkx2.5), GATA binding protein 4 (GATA-4), myocyte-spe-
cific enhancer factor 2C (MEF2C).73 Also, they display sponta-
naneous beating activity with characteristic atrial, ventricular,
and nodal action potentials.74,75 The strong cardiogenic poten-
tial of ESCs and the availability of human ESC–derived car-
diomyocytes have motivated research into their effects in HF.
In the only study of these cells performed in a large animal
model to date, Ménard et al80 reported that cardiac-committed
mouse ESCs, transplanted into infarcted sheep myocardium,
differentiated into cardiomyocytes and improved LV function.
Similarly, using human ESC–derived cardiomyocytes, Caspi
et al77 and Cai et al78 reported formation of stable cardiomyo-
cyte grafts, attenuation of LV remodeling, and improvement in
LV systolic function in rat models of old MI (although in the
latter study,78 they caused formation of teratomas).

Despite the well-documented capacity of ESCs for car-
diac differentiation, both ethical and biological concerns
have prevented their use as a treatment modality in patients.

Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMMNC</td>
<td>bone marrow mononuclear cell</td>
</tr>
<tr>
<td>CABG</td>
<td>coronary artery bypass grafting</td>
</tr>
<tr>
<td>CDC</td>
<td>cardiophere-derived cell</td>
</tr>
<tr>
<td>CSC</td>
<td>cardiac stem cell</td>
</tr>
<tr>
<td>ECM</td>
<td>extracellular matrix</td>
</tr>
<tr>
<td>EPC</td>
<td>endothelial progenitor cell</td>
</tr>
<tr>
<td>ESC</td>
<td>embryonic stem cell</td>
</tr>
<tr>
<td>HF</td>
<td>heart failure</td>
</tr>
<tr>
<td>HSC</td>
<td>hematopoietic stem cell</td>
</tr>
<tr>
<td>iPSC</td>
<td>induced pluripotent stem cells</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricular</td>
</tr>
<tr>
<td>LVEF</td>
<td>left ventricular ejection fraction</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>MMP</td>
<td>matrix metalloproteinase</td>
</tr>
<tr>
<td>MSC</td>
<td>mesenchymal stem cell</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York Heart Association</td>
</tr>
</tbody>
</table>

Figure 1. Use of various types of stem cell therapies in patients with cardiovascular disease. Illustrated is the number of patients treated with 6 major types of cells from 2000 (when the first cell therapy for heart disease was performed) to 2012.
Specifically, because of their pluripotency and allogeneic nature, adoptive transfer of ESCs is plagued by teratoma formation and graft rejection, formidable problems that essentially preclude the clinical use of these cells. In contemporary clinical research, the margin of tolerance for such catastrophic effects as tumor formation is zero and, no matter how much the probability of tumors is reduced by various ESC manipulations, it is unlikely that it will be completely eliminated. One teratoma would be sufficient to halt clinical investigation of ESCs for years. However, the recent emergence of induced pluripotent stem cells (iPSCs), which have pluripotency comparable with ESCs, has provided an alternative that obviates one of the major problems inherent in ESC-based therapies, graft rejection.

For ESCs, the chasm between promises made and results delivered has been striking. Since the late 1990s, these cells have been enthusiastically heralded as a major breakthrough in medicine that will usher in unprecedented opportunities for the treatment of human disease. Despite these claims, however, no clinical trial of ESCs in cardiovascular disease has been performed or even initiated nor, to the best of our knowledge, is any such trial even being planned. During the same time frame, adult stem cells have been used safely in thousands of patients, with results that were sufficiently encouraging to warrant phase II and phase III trials. Clearly, the expectations raised by the advocates of ESCs have not been met. This sobering realization, coupled with the problems of tumorigenesis and rejection, makes it unlikely that enthusiasm for the therapeutic use of ESCs will continue unabated. The most reasonable interpretation of current knowledge is that ESC-based therapies have no future in terms of clinical application, at least in the next few years, and will probably become obsolete, a thing of the past, which will be remembered as an unfulfilled promise.

**Induced Pluripotent Stem Cells**

In 2006, Takahashi and Yamanaka produced a population of iPSCs by transducing mouse adult fibroblasts with defined transcription factors (octamer-binding transcription factor 3/4 [OCT3/4], sex determining region Y-box 2 [Sox-2], c-Myc, Kruppel-like factor 4 [Klf4]; the Yamanaka factors). These iPSCs express ESC surface markers and exhibit morphology and growth properties similar to those of ESCs. It was subsequently demonstrated that the cardiogenic potential of iPSCs is very similar to that of ESCs, and that iPSC-derived cardiomyocytes possess functional properties typical of cardiac cells, such as spontaneous beating, contractility, and ion channel expression. However, to date, no study has specifically assessed the therapeutic potential of iPSCs in animal models of HF.

Although iPSCs hold great promise for cardiac regeneration, the transcription factors used to generate these cells (c-Myc, Oct4, and Kruppel-like factor 4) are known oncogenes that can produce teratomas. Newer methods that involve transient expression of the reprogramming factors may obviate this problem, but the pluripotent nature of these cells may still promote tumorigenesis. Other problems include the low efficiency of iPSC generation and the variability from one cell line to another. Given the rapidly evolving technology in this field, it is possible that these technical hurdles will soon be overcome, and that iPSC-based approaches will prove to be helpful for the therapy of HF; at present, however, iPSCs are not ready for clinical application.

**Skeletal Myoblasts**

Skeletal myoblasts are derived from satellite cells, a skeletal muscle progenitor cell population present under the basal membrane of myofibers. With muscle injury, these satellite cells undergo proliferation and promote regeneration by differentiating into myotubes and new muscle fibers. Because of their ease of procurement from muscle biopsies, rapidly...
Table 1. Animal Studies of Stem Cell Therapy in Heart Failure

<table>
<thead>
<tr>
<th>Study</th>
<th>Host</th>
<th>Type of Heart Failure</th>
<th>Time of Cell Therapy</th>
<th>Dose and Route of Administration</th>
<th>Follow-Up Period After Cell Therapy</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skeletal myoblasts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Suzuki et al | Lewis rat | Doxorubicin-induced cardiomyopathy | 4 wk after last doxorubicin dose | 1×10⁶ cells, intracoronary | 4 wk | ↓ Mortality
Improved hemodynamic parameters |
| Ghostine et al | Sheep | Embolization using absorbable hemostatic gauze | 14 d after MI | 50,000 cells, intramyocardial | 12 mo | ↑ LVEF
↓ LVEDV
Improved global wall motion score |
| Pouly et al | CHF147 Syrian hamster | δ-sarcoglycan deficiency-induced dilated cardiomyopathy | ... | 5×10⁴ cells, intramyocardial | 4 wk | ↑ FAC
↓ Fibrosis |
| Chachques et al | Sheep | Permanent coronary occlusion | 3 wk after MI | 70×10⁶ cells, intramyocardial | 3 mo | ↑ LVEF
↓ LV remodeling |
| He et al | Dog | Coronary microembolization | After hemodynamic confirmation of establishment of heart failure | 270 to 830×10⁶ cells, intramyocardial | 10 wk | ↑ LVEF
↓ LV remodeling
Improved hemodynamic parameters |
| Gavira et al | Gottingen mini-pig | Vascular embolization in the intermediate branch of first or second marginal artery | 8 wk after MI | 407.55±115×10⁶, intramyocardial or intracoronary | 3 mo | ↑ LVEF
↑ Fibrosis
↑ Vasculogenesis |
| Farahmand et al | Lewis rat | Permanent coronary occlusion | Either 5 d after MI or 30 d after MI | 5×10⁴ cells, intramyocardial | 30 d | ↑ LVFS
↓ LV remodeling
Improved hemodynamic parameters
Attenuated matrix remodeling |
| Fukushima et al | Sprague-Dawley rat | Permanent coronary occlusion | 3 wk after MI | 5×10⁴ cells, intramyocardial or intracoronary | 84 d | ↑ LVEF
Improved physical activity ↔ Mortality |
| **Bone marrow mononuclear cells** |      |                       |                      |                                   |                                     |          |
| Tomita et al | Sprague-Dawley rat | Cryosurgery | 3 wk after surgery | 1×10⁴ cells, intramyocardial | 3 wk | Improved hemodynamic parameters
↓ LV remodeling
↑ Angiogenesis
Cardiac differentiation + |
| Bel et al | Sheep | Ligation of circumflex artery | 3 wk after MI | 422×10⁶ cells, intramyocardial | 2 mo | ↔ LVEF
 ↔ LV remodeling
No differentiation into endothelial cells or cardiomyocytes |
| Waksman et al | Pig | Permanent coronary occlusion | 4 wk after MI | 24×10⁶ cells, intramyocardial | 4 wk | ↔ Global wall motion score
↓ Infarct size
↑ Angiogenesis |
| **Bone marrow– and adipose-derived mesenchymal cells** |      |                       |                      |                                   |                                     |          |
| Nagaya et al | Lewis rat | Myosin-induced autoimmune myocarditis | 5 wk after immunization | 5×10⁴ cells, intramyocardial | 4 wk | Improved hemodynamic parameters
↑ Angiogenesis
Cardiac differentiation + |
| Silva et al | Bone marrow MSCs | Ameroid-induced chronic coronary occlusion | 30 d after MI | 100×10⁶ cells, intramyocardial | 30 d | ↑ LVEF
Neovascularization + |
| Miyahara et al (adipose-derived MSCs) | Sprague-Dawley rat | Permanent coronary occlusion | 4 wk after MI | 5–8×10⁶ cells as monolayered grafts into myocardium | 4 wk | ↓ Mortality
Improved hemodynamic parameters
Cardiac regeneration + |

(Continued)
of expansion in vitro, and resistance to hypoxic and ischemic conditions.

Skeletal myoblasts were the first cells to be tested both in preclinical and clinical studies of HF. However, myoblasts transplanted in injured hearts have been found to form skeletal (striated) muscle fibers rather than cardiac muscle fibers.

<table>
<thead>
<tr>
<th>Study</th>
<th>Host</th>
<th>Type of Heart Failure</th>
<th>Time of Cell Therapy</th>
<th>Dose and Route of Administration</th>
<th>Follow-Up Period After Cell Therapy</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu et al (bone marrow MSCs)</td>
<td>Sprague-Dawley rat</td>
<td>Permanent coronary occlusion</td>
<td>4 wk after MI</td>
<td>$1 \times 10^6$ cells, intramyocardial</td>
<td>4 wk</td>
<td>↓ Infarct size, ↓ LV remodeling, ↑ LVEF, ↓ Fibrosis, Cardiac differentiation +, ↑ Angiogenesis</td>
</tr>
<tr>
<td>Mazo et al (adipose-derived MSCs)</td>
<td>Sprague-Dawley rat</td>
<td>Permanent coronary occlusion</td>
<td>5 wk after MI</td>
<td>$1 \times 10^6$ cells, intramyocardial</td>
<td>3 mo</td>
<td>↑ LVEF, Improved tissue metabolism, ↓ Infarct size, ↓ Fibrosis, Neovascularization +</td>
</tr>
<tr>
<td>Li et al (bone marrow MSCs)</td>
<td>Wistar rat</td>
<td>Isoproterenol-induced heart failure</td>
<td>4 wk after isoproterenol injection</td>
<td>$3 \times 10^6$ cells, intramyocardial</td>
<td>4 wk</td>
<td>↑ LVEF, Fibrosis, Cardiac differentiation +</td>
</tr>
<tr>
<td>Schuleri et al (bone marrow MSCs)</td>
<td>Gottingen pig</td>
<td>Ischemia/reperfusion injury</td>
<td>12 wk after MI</td>
<td>$20 \times 10^6$ to $200 \times 10^6$ cells, intramyocardial</td>
<td>24 wk</td>
<td>High dose: ↑ LVEF, ↓ Infarct size, Both high and low dose: ↑ Regional contractility and myocardial blood flow</td>
</tr>
<tr>
<td>Mazo et al (bone marrow MSCs)</td>
<td>Sprague-Dawley rat</td>
<td>Permanent coronary occlusion</td>
<td>4 wk after MI</td>
<td>$1 \times 10^6$ cells, intramyocardial</td>
<td>4 wk</td>
<td>↑ LVEF, Fibrosis, Angiogenesis</td>
</tr>
<tr>
<td>Cardiac stem cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rota et al (c-kit+ cells)</td>
<td>Fischer 344 rat</td>
<td>Permanent coronary occlusion</td>
<td>20 d after MI</td>
<td>$40 \times 10^6$ cells, intramyocardial</td>
<td>2 wk</td>
<td>↑ LVEF, Attenuated matrix remodeling, Cardiac regeneration +, Neovascularization +, Improved hemodynamic parameters, ↓ LV remodeling</td>
</tr>
<tr>
<td>Johnston et al (CDCs)</td>
<td>Mini-pig</td>
<td>Permanent coronary occlusion</td>
<td>4 wk after MI</td>
<td>$10 \times 10^6$ cells, intracoronary</td>
<td>8 wk</td>
<td>↓ Infarct size, Improved hemodynamic parameters, ↔ LVEDV, ↓ LV remodeling, Cardiac regeneration +</td>
</tr>
<tr>
<td>Tang et al (c-kit+ cells)</td>
<td>Fischer 344 rat</td>
<td>Ischemia/reperfusion injury</td>
<td>30 d after MI</td>
<td>$40 \times 10^6$ cells, intracoronary</td>
<td>35 d</td>
<td>↑ LVEF, Improved hemodynamic parameters, Attenuated matrix remodeling, ↓ Fibrosis, ↓ LV remodeling, Cardiac regeneration +</td>
</tr>
<tr>
<td>Lee et al (cardiospheres)</td>
<td>Mini-pig</td>
<td>Permanent coronary occlusion</td>
<td>4 wk after MI</td>
<td>$1 \times 10^6$ cells, intracoronary</td>
<td>8 wk</td>
<td>↑ LVEF, ↓ LV remodeling</td>
</tr>
<tr>
<td>Bolli et al (c-kit+ cells)</td>
<td>Pig</td>
<td>Ischemia/reperfusion injury</td>
<td>90 d after MI</td>
<td>$50 \times 10^6$ cells, intracoronary</td>
<td>31 d</td>
<td>↑ LVEF, Improved hemodynamic parameters, ↓ Fibrosis, ↓ LV remodeling, Cardiac regeneration +, Angiogenesis +</td>
</tr>
</tbody>
</table>

↑ indicates increased; ↓, decreased; ↔, no change; CDC, cardiosphere-derived cell; FAC, fractional area change; LV, left ventricular; LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; LVFS, LV fractional shortening; MI, myocardial infarction; and MSC, mesenchymal stem cell.
<table>
<thead>
<tr>
<th>Study/Name of the Trial</th>
<th>Study Design</th>
<th>No. of Patients</th>
<th>Delivery Method</th>
<th>Cell Dose</th>
<th>End Point Evaluation Method</th>
<th>Follow-Up Period</th>
<th>Outcomes</th>
<th>Side Effects in Cell-Treated Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skeletal myoblasts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Menasche et al&lt;sup&gt;31&lt;/sup&gt;</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=10; no controls</td>
<td>Intramyocardial injection during CABG</td>
<td>871×10⁶ cells</td>
<td>Echocardiography</td>
<td>10.9 mo</td>
<td>↑ LVEF, ↑ Regional wall motion, ↓ NYHA class</td>
<td>Ventricular arrhythmias in 4/10 patients, 2 deaths</td>
</tr>
<tr>
<td>Smits et al&lt;sup&gt;32&lt;/sup&gt;</td>
<td>Nonrandomized, uncontrolled pilot study</td>
<td>Cell treatment=5; no controls</td>
<td>Intramyocardial (transendocardial)</td>
<td>196±105×10⁶ cells</td>
<td>MRI, LV angiography, nuclear radiography, echocardiography</td>
<td>3 to 6 mo</td>
<td>↑ Wall thickening, ↑ LVEF, ↑ Regional wall motion at 3 mo but not at 6 mo</td>
<td>Ventricular arrhythmias in 1/5 patients</td>
</tr>
<tr>
<td>Herreros et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=12; no controls</td>
<td>Intramyocardial injection during CABG</td>
<td>221×10⁶</td>
<td>Echocardiography, PET scan</td>
<td>3 mo</td>
<td>↑ LVEF, ↑ Myocardial contractility and tissue viability, ↑ Regional wall motion</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Siminiak et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=10; no controls</td>
<td>Intramyocardial injection during CABG</td>
<td>4×10⁹ cells</td>
<td>Echocardiography</td>
<td>12 mo</td>
<td>↑ Contractility, ↑ LVEF, ↑ Regional wall motion</td>
<td>Ventricular arrhythmias in 4/10 patients, 1 death</td>
</tr>
<tr>
<td>Ince et al&lt;sup&gt;35&lt;/sup&gt;</td>
<td>Nonrandomized, case-controlled study</td>
<td>Cell treatment=6; controls=6</td>
<td>Intramyocardial (transendocardial)</td>
<td>210±150×10⁶ cells</td>
<td>Echocardiography</td>
<td>12 mo</td>
<td>↑ LVEF, ↑ Walking distance, ↓ NYHA class</td>
<td>Two patients developed early ventricular arrhythmias, which was not sustained</td>
</tr>
<tr>
<td>Siminiak et al&lt;sup&gt;36&lt;/sup&gt; (POZNAN)</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=10; no controls</td>
<td>Percutaneous transcoronary-venous</td>
<td>100×10⁶ cells</td>
<td>Echocardiography</td>
<td>6 mo</td>
<td>↓ NYHA class, ↑ LVEF</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Dib et al&lt;sup&gt;37&lt;/sup&gt;</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=30; no controls</td>
<td>Intramyocardial injection during CABG (24 patients) and LVAD (6 patients)</td>
<td>CABG group: 10, 30, 100, 300×10⁶ cells; LVAD group: 300×10⁶ cells</td>
<td>Echocardiography, PET scan</td>
<td>24 mo</td>
<td>↑ LVEF, ↑ Regional wall motion, ↑ Viability, ↓ LVESV and LVEDV, ↓ NYHA class</td>
<td>CABG group: Ventricular arrhythmias in 4/24 patients, 1 death and 1 MI; LVAD group: Ventricular arrhythmias in 2/6 patients, 3 deaths</td>
</tr>
<tr>
<td>Biagini et al&lt;sup&gt;38&lt;/sup&gt;</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=10; no controls</td>
<td>Intramyocardial (transendocardial)</td>
<td>15×10⁶ cells</td>
<td>Echocardiography</td>
<td>12 mo</td>
<td>↑ LVEF, ↓ LVESV, ↓ NYHA class</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Hagège et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Cohort study</td>
<td>Cell treatment=9; no controls</td>
<td>Intramyocardial injection during CABG</td>
<td>62 to 1100×10⁶ (871×10⁶) cells</td>
<td>Echocardiography</td>
<td>18–58 (49.4) months</td>
<td>↑ LVEF, ↓ NYHA class</td>
<td>Ventricular arrhythmias in 5/9 patients</td>
</tr>
<tr>
<td>Gavira et al&lt;sup&gt;40&lt;/sup&gt;</td>
<td>Nonrandomized, controlled study</td>
<td>Cell treatment=12; controls=14</td>
<td>Intramyocardial injection during CABG</td>
<td>50×10⁶ cells</td>
<td>Echocardiography, PET scan</td>
<td>12 mo</td>
<td>↑ LVEF, ↑ Perfusion and viability, ↑ Regional contractility</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Veitman et al&lt;sup&gt;41&lt;/sup&gt;</td>
<td>Nonrandomized, controlled study</td>
<td>Cell treatment=14; controls=28</td>
<td>Intramyocardial (transendocardial)</td>
<td>3 to 50×10⁶ cells</td>
<td>Echocardiography</td>
<td>4 y</td>
<td>↓ LVEF, ↔ Myocardial performance index</td>
<td>Ventricular arrhythmias in 7 cell-treated patients, 3 and 11 deaths in cell-treated and control groups, respectively. (Continued)</td>
</tr>
<tr>
<td>Study/Name of the Trial</td>
<td>Study Design</td>
<td>No. of Patients</td>
<td>Delivery Method</td>
<td>Cell Dose</td>
<td>End Point Evaluation Method</td>
<td>Follow-Up Period</td>
<td>Outcomes</td>
<td>Side Effects in Cell-Treated Patients</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Menasché et al52 (MAGIC)</td>
<td>Randomized, placebo-controlled, double-blind study</td>
<td>107</td>
<td>Intramyocardial injection during CABG</td>
<td>Low dose: $400\times10^6$ High dose: $800\times10^6$ cells</td>
<td>Intracoronary SPECT</td>
<td>6 mo</td>
<td>LVEF Improved Wall Motion</td>
<td>Low dose: 4 patients with ventricular arrhythmias and 5 deaths</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Echocardiography</td>
<td></td>
<td>↓NYHA class, ↓LV dimension</td>
<td>Ventricular arrhythmias in 6/12 patients</td>
</tr>
<tr>
<td>Dib et al53 (CAUSMIC)</td>
<td>Randomized, placebo-controlled, double-blind study</td>
<td>24</td>
<td>Intramyocardial injection during CABG</td>
<td>Low dose: $400\times10^6$ High dose: $800\times10^6$ cells</td>
<td>Doubutamine stress echocardiography</td>
<td>6 mo</td>
<td>LVEF Improved Wall Motion</td>
<td>Ventricular arrhythmias in 12/26 patients, 1 death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MUGA scan</td>
<td></td>
<td>↓NYHA class, ↑LV dimension</td>
<td>Ventricular arrhythmias in 7/15 cell-treated patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Echocardiography</td>
<td></td>
<td>↑LVF, ↑6MWD</td>
<td>One sudden cardiac death in cell-treated group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No major complications reported</td>
<td></td>
</tr>
<tr>
<td>Povsic et al55</td>
<td>Randomized, double-blind, controlled study</td>
<td>15</td>
<td>Intramyocardial injection during CABG</td>
<td>Low dose: $400\times10^6$ High dose: $800\times10^6$ cells</td>
<td>Doubutamine stress echocardiography</td>
<td>6 mo</td>
<td>↑LVF, ↑6MWD</td>
<td>No major complications reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No major complications reported</td>
<td></td>
</tr>
<tr>
<td>Bone marrow mononuclear cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No major complications reported</td>
<td></td>
</tr>
<tr>
<td>Perin et al46</td>
<td>Prospective, nonrandomized, open-label study</td>
<td>14</td>
<td>Intramyocardial injection during CABG</td>
<td>$25.6\pm6.3\times10^6$ cells</td>
<td>Echocardiography, SPECT</td>
<td>2 and 4 mo</td>
<td>↑LVEF, ↓LV dimension</td>
<td>No major complications reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓NYHA class, ↓LV dimension</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↑LVEF, ↓6MWD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓LVESV, ↓LVEDV, ↓Regional wall motion ↑Viability</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓LV dimension</td>
<td></td>
</tr>
<tr>
<td>Galíñanes et al44</td>
<td>Nonrandomized, uncontrolled study</td>
<td>14</td>
<td>Intramyocardial injection during CABG</td>
<td>$25.6\pm6.3\times10^6$ cells</td>
<td>Echocardiography, SPECT</td>
<td>6 and 12 mo</td>
<td>↑Exercise capacity ↑Perfusion ↑LVF</td>
<td>No major complications reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No major complications reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No major complications reported</td>
<td></td>
</tr>
<tr>
<td>Blatt et al38</td>
<td>Nonrandomized, uncontrolled study</td>
<td>6</td>
<td>Intracoronary injection during CABG</td>
<td>$16.7\times10^6$ cells</td>
<td>Doubutamine stress echocardiography</td>
<td>4 mo</td>
<td>↑LVF, ↓NYHA class</td>
<td>No major complications reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Improved Wall Motion Score</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No major complications reported</td>
<td></td>
</tr>
<tr>
<td>Assmus et al39 (TOPCARE-CHD)</td>
<td>Randomized, controlled study</td>
<td>52</td>
<td>Intracoronary injection during CABG</td>
<td>$205\pm110\times10^6$ Circulating progenitor cells: $22\pm11\times10^6$ cells</td>
<td>Echocardiography, SPECT, MRI</td>
<td>3 mo</td>
<td>LVEF (BMCs only), ↓NYHA class (BMCs only)</td>
<td>One episode of ventricular arrhythmia and 5 deaths in circulating progenitor cell group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓LVESV, ↓LVEDV, ↓Regional wall motion ↑Viability</td>
<td></td>
</tr>
<tr>
<td>Hendrikkx et al31</td>
<td>Randomized, controlled trial</td>
<td>10</td>
<td>Intramyocardial injection during CABG</td>
<td>$60\pm31\times10^6$ cells</td>
<td>MRI</td>
<td>4 mo</td>
<td>↑Systolic thickening ↓NYHA class and LVESV</td>
<td>No major complications reported</td>
</tr>
</tbody>
</table>

(Continued)
Table 2. Continued

<table>
<thead>
<tr>
<th>Study/Name of the Trial</th>
<th>Study Design</th>
<th>No. of Patients</th>
<th>Delivery Method</th>
<th>Cell Dose</th>
<th>End Point Evaluation Method</th>
<th>Follow-Up Period</th>
<th>Outcomes</th>
<th>Side Effects in Cell-Treated Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gao et al\textsuperscript{52}</td>
<td>Nonrandomized, controlled study</td>
<td>Cell treatment=14; controls=14</td>
<td>Intracoronary</td>
<td>28 to 32 ( \times 10^6 ) cells</td>
<td>Echocardiography</td>
<td>3 mo</td>
<td>( \uparrow ) LVEF</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Seth et al\textsuperscript{53}</td>
<td>Pilot study</td>
<td>Cell treatment=24; controls=120</td>
<td>Intracoronary</td>
<td>( \approx 120 \times 10^6 ) cells</td>
<td>Echocardiography</td>
<td>3 mo</td>
<td>( \uparrow ) LVEF ( \downarrow ) LVESV ( \uparrow ) NYHA class</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Beeres et al\textsuperscript{54}</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=15; no controls</td>
<td>Intramyocardial (transendocardial)</td>
<td>( 94\pm14 \times 10^6 ) cells</td>
<td>SPECT</td>
<td>3 mo</td>
<td>( \uparrow ) LVEF ( \downarrow ) NYHA class ( \uparrow ) Perfusion ( \uparrow ) Regional wall motion</td>
<td>One death due to heart failure</td>
</tr>
<tr>
<td>Yao et al\textsuperscript{55}</td>
<td>Randomized, placebo-controlled trial</td>
<td>Cell treatment=24; controls=23</td>
<td>Intracoronary</td>
<td>( 12 \times 10^6 ) cells</td>
<td>Echocardiography, MRI, SPECT</td>
<td>6 mo</td>
<td>( \leftrightarrow ) LVEF ( \leftrightarrow ) LVEDV and LVESV ( \leftrightarrow ) Perfusion ( \leftrightarrow ) Infarct size</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Ang et al\textsuperscript{56}</td>
<td>Randomized, controlled, single-blinded trial</td>
<td>Cell treatment=42 (21 intramyocardial, 21 intracoronary); controls=23</td>
<td>Intramyocardial injection during CABG or intracoronary</td>
<td>Intramyocardial: ( 84\pm56 \times 10^6 ) BMCs and ( 142\pm166 \times 10^6 ) CD34+/CD177+ cells Intracoronary: ( 119\pm73 \times 10^6 ) BMCs and ( 249\pm264 \times 10^6 ) CD34+/CD177+ cells</td>
<td>Echocardiography, MRI</td>
<td>6 mo</td>
<td>( \leftrightarrow ) LVEF ( \leftrightarrow ) LVEDV and LVESV ( \leftrightarrow ) Perfusion ( \leftrightarrow ) Infarct size</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Diederichsen et al\textsuperscript{57}</td>
<td>Nonrandomized, uncontrolled study</td>
<td>Cell treatment=32; no controls</td>
<td>Repeated intracoronary</td>
<td>First infusion: ( 647\pm382 \times 10^6 ) cells Second infusion: ( 889\pm561 \times 10^6 ) cells</td>
<td>Echocardiography</td>
<td>12 mo</td>
<td>( \uparrow ) LVEF improved LV filling</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Perin et al\textsuperscript{58} (FOCUS-HF)</td>
<td>Randomized, double-blind, controlled study</td>
<td>Cell treatment=20; controls=10</td>
<td>Intramyocardial (transendocardial)</td>
<td>( 30 \times 10^6 ) cells</td>
<td>Echocardiography, SPECT</td>
<td>6 mo</td>
<td>( \uparrow ) LVEF ( \uparrow ) CCSAS ( \uparrow ) Perfusion</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Hare et al\textsuperscript{59} (POSEIDON)</td>
<td>Randomized pilot Study</td>
<td>Cell treatment=31; no controls</td>
<td>Intramyocardial (transendocardial)</td>
<td>Three different doses: 20, 100, ( 200 \times 10^6 )</td>
<td>Computed tomography</td>
<td>12 mo</td>
<td>( \uparrow ) LVEF Improved physical performance ( \downarrow ) LVEDV</td>
<td>One patient in each group was hospitalized for HF</td>
</tr>
<tr>
<td>Patel et al\textsuperscript{60}</td>
<td>Randomized, controlled study</td>
<td>Cell treatment=10; controls=10</td>
<td>Intramyocardial injection during CABG</td>
<td>( 22 \times 10^6 ) cells</td>
<td>Echocardiography, SPECT</td>
<td>6 mo</td>
<td>( \uparrow ) LVEF</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Manginas et al\textsuperscript{61}</td>
<td>Pilot, controlled study</td>
<td>Cell treatment=12; controls=12</td>
<td>Intracoronary</td>
<td>( CD133^+ : \ 16.9\pm4.9 \times 10^6 ) cells ( CD133^-/CD34^+ : \ 8.4\pm10^5 ) cells</td>
<td>Echocardiography</td>
<td>28\pm8.7 mo</td>
<td>( \uparrow ) LVEF ( \uparrow ) LV remodeling ( \downarrow ) LVESV and LVEDV ( \uparrow ) Perfusion</td>
<td>One patient developed restenosis at the cell delivery site</td>
</tr>
<tr>
<td>Stamm et al\textsuperscript{62}</td>
<td>Nonrandomized, controlled study</td>
<td>Cell treatment=20; controls=20</td>
<td>Intramyocardial injection during CABG</td>
<td>( 5.8 \times 10^7 ) cells</td>
<td>Echocardiography, SPECT</td>
<td>6 mo</td>
<td>( \uparrow ) LVEF ( \uparrow ) Perfusion</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Fischer-Rasokat et al\textsuperscript{63}</td>
<td>Pilot study</td>
<td>Cell treatment=33; no controls</td>
<td>Intracoronary</td>
<td>( 259\pm135 \times 10^6 ) cells</td>
<td>MRI, LV angiography</td>
<td>3 mo, 12 mo</td>
<td>( \uparrow ) LVEF improved regional wall motion</td>
<td>No major complications reported</td>
</tr>
</tbody>
</table>

(Continued)
The ability of skeletal myoblasts to promote cardiac repair has been evaluated in small animal models of HF. Both after intramyocardial and intracoronary administration, these cells have been shown to differentiate into myotubes and form viable skeletal muscle-like grafts in the scarred myocardium, which was associated with attenuation of adverse ventricular remodeling, decreased interstitial fibrosis, and improvement of cardiac performance. The reduction in fibrosis has been ascribed to correction of the imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs. The ability of skeletal myoblasts to improve cardiac function has also been shown in nonischemic cardiomyopathy (induced by doxorubicin and δ-sarcoglycan gene mutation in rats and CHF147 Syrian hamsters, respectively); in both studies, intramyocardial injection of myoblasts improved LV function and decreased interstitial fibrosis. In the latter study, the benefits were ascribed to extracellular matrix (ECM) remodeling and activation of cardiac stem cells (CSCs) secondary to the secretion of growth factors.

These encouraging results from animal studies were quickly translated into clinical trials in HF. The first human transplantation of myoblasts was performed by Menasche et al in patients with severe ischemic HF (Figure 1). In this phase I study, injection of 871 million cells into a scarred LV region at the time of coronary artery bypass grafting (CABG) was associated with a significant improvement in New York Heart Association (NYHA) functional class and LV function. These observations, however, were difficult to interpret because of the confounding effects of concomitant surgical revascularization and lack of a suitable control group. Furthermore, 4 of 10 patients experienced ventricular tachycardia, warranting the use of implantable cardioverter-defibrillators. This electric instability has been ascribed to the lack of electromechanical coupling because of the failure of differentiated myotubes to express key gap junction proteins such as N-cadherin and connexin-43.

After this trial, several small, nonrandomized studies showed augmented LV function, improved LV remodeling, and histological evidence of myoblast survival in the myocardium after intramyocardial injection in patients with ischemic cardiomyopathy. Based on the promising results of these studies, Menasche et al performed The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC), a phase II randomized, placebo-controlled, double-blind trial that examined the effects of intramyocardial injection of skeletal myoblasts (at 2 doses: 400 or 800 millions) plus CABG versus CABG alone (controls) in 97 patients with severe LV dysfunction (LV ejection fraction [LVEF] between 15% and 35%). There were no significant differences in cardiac function and occurrence of malignant arrhythmias between patients receiving myoblasts and controls at the end of 6 months; however, in a substudy, it was found that patients treated with 800 million cells had attenuation of LV remodeling and a decrease in LV volumes.

Other investigators have used catheter-based intramyocardial injection of skeletal myoblasts in ischemic HF. A small (10 patients) phase I study of percutaneous transcoronary-venous myoblast transplantation (Percutaneous Transcoronary-venous Transplantation of Autologous Skeletal Cell-Treated Patients).

<table>
<thead>
<tr>
<th>Study/Name of the Trial</th>
<th>Study Design</th>
<th>No. of Patients</th>
<th>Delivery Method</th>
<th>Cell Dose</th>
<th>End Point Evaluation Method</th>
<th>Follow-Up Period</th>
<th>Outcomes</th>
<th>Side Effects in Cell-Treated Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vrtovec et al (SCIPIO)</td>
<td>Randomized, controlled study</td>
<td>Cell treatment=10; controls=10</td>
<td>Intramyocardial (transendocardial)</td>
<td>2.37±1.31×10⁶ cells</td>
<td>Echocardiography</td>
<td>6 mo</td>
<td>↓ LVEDV improved maximal oxygen consumption</td>
<td>No major complications reported</td>
</tr>
<tr>
<td>Perin et al (CADUCEUS)</td>
<td>Randomized, controlled study</td>
<td>Cell treatment=17; controls=8</td>
<td>Intracoronary</td>
<td>1.25–25×10⁶ cells</td>
<td>MRI</td>
<td>6 mo</td>
<td>↓ LVEF ↓ NYHA class</td>
<td>No major complications reported</td>
</tr>
</tbody>
</table>

† indicates increased; ↓, decreased; ↔, no change; BMC, bone marrow cell; CABG, coronary artery bypass grafting; CCSAS, Canadian Cardiovascular Society Angina Score; LV, left ventricular; LVAD, LV assist device; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; LVEF, LV ejection fraction; MAGIC, The Myoblast Autologous Grafting in Ischemic Cardiomyopathy; MUGA, Multigated acquisition scan; MWD, minute walk distance, NYHA, New York Heart Association; PET, positron emission tomography; and SPECT, single photon emission computed tomography. |
Myoblasts in the Treatment of Post-infarction Myocardial Contractility Impairment [POZAN] trial\(^{36}\) reported an improvement in NYHA class and LVEF at 6 months of follow-up. Other studies in small patient cohorts by Biagini et al\(^{38}\) and Dib et al\(^{41}\) (Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System [CauSMIC] trial) reported improved NYHA functional class and increased LVEF at 1 year after therapy; however, in the former study,\(^{38}\) the improvement in LV function was noted only during dobutamine infusion. A double-blind, randomized, placebo-controlled, multicenter study of transcatheter intramyocardial administration of myoblasts in HF (To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction [MARVEL] trial), designed to enroll 330 patients, was terminated prematurely because of financial constraints; the preliminary results in 23 patients showed improvement in 6-minute walk distance at 3 and 6 months, and an increase in the occurrence of sustained ventricular tachycardia in 7 of 15 patients.\(^{35}\)

The long-term effects of intramyocardial myoblast injection in patients with ischemic cardiomyopathy have been evaluated in 4 trials\(^{37,39-41}\) (including a follow-up of the first Menasche study).\(^{39}\) Although in 3 of these trials\(^{37,39-41}\) cardiac function improved, myoblasts were transplanted during surgical revascularization (CABG) or LV assist device placement, which, as pointed out above, complicates the interpretation of the outcome. In the fourth study,\(^{41}\) in which myoblasts were delivered percutaneously by transendocardial injection, there was no beneficial effect on global or regional LV function at 4-year follow-up. These findings are consistent with the results of the Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter (SEISMIC) trial, a recent phase Ia, randomized, open-label trial of percutaneous intramyocardial transplantation of myoblasts in patients with HF.\(^{44}\) In this study, myoblast therapy was not associated with any improvement in LVEF at 6-month follow-up, although there was an improvement in 6-minute walk distance.\(^{44}\)

In summary, most of the smaller, nonrandomized clinical trials of skeletal myoblasts have yielded encouraging results, but the largest study to date (the MAGIC trial) failed to corroborate these findings. It must also be noted that many of these trials were performed in conjunction with CABG or LV assist device procedures, making it difficult to separate the effects of myoblasts from those of revascularization. Because of the negative results of MAGIC, the risk of arrhythmias, and the availability of other cell types, interest in skeletal myoblasts has waned, and it seems unlikely that these cells will play a role in cell therapy of HF.

**Bone Marrow–Derived Stem Cells**

The bone marrow harbors different types of hematopoietic and nonhematopoietic stem cell (HSC) populations that have the potential to differentiate into diverse phenotypes (Figure 2). Because of the relatively greater concentration of stem cells in the bone marrow and the ease of procurement of these cells, most of the preclinical and clinical studies in HF have used bone marrow–derived stem cells (Figure 1; Tables 1 and 2).

**Unfractionated Bone Marrow Mononuclear Cells**

Bone marrow mononuclear cells (BMMNCs) are a heterogeneous population composed of mesenchymal stem cells (MSCs), HSCs, endothelial progenitor cells (EPCs), and more committed cell lineages. Because BMMNCs can be easily procured using density gradient centrifugation and because these cells do not require extensive culture techniques, they have been used by many investigators in animal models of acute MI.\(^{3,105,106}\) Relatively fewer studies have been performed in the setting of chronic HF, and the results are conflicting. In sheep\(^{46}\) and pig\(^{47}\) models of postinfarction HF, BMMNCs (injected directly into the scar tissue) produced no improvement in LV function (although a study reported increased angiogenesis and reduction in infarct size).\(^{17}\) In contrast to these findings, studies in dogs (postinfarction HF)\(^{107}\) and rats (cryoinjury-induced HF)\(^{15}\) have reported improvement in myocardial function, reduction in plasma N-terminal probrain natriuretic peptide levels, and induction of angiogenesis.

Conflicting results have also been obtained in patients with HF. Perin et al\(^{46,47}\) were the first to evaluate the safety and efficacy of autologous BMMNCs, injected transendocardially with an NOGA Myostar catheter, in patients with chronic ischemic HF (Figure 1). At 2 and 4 months after therapy, there was a significant improvement in LVEF and a reduction in end-systolic volume in cell-treated patients.\(^{46}\) During longer follow-up (6 and 12 months), these patients exhibited not only improved cardiac performance but also an increase in myocardial perfusion and exercise capacity compared with controls.\(^{57,58}\) Directionally concordant observations were made by other investigators, who reported that intramyocardial injection of BMMNCs (performed during surgery\(^{40}\) or percutaneously via a NOGA device)\(^{32}\) was associated with a decrease in HF symptoms and an improvement in LV function in patients with severe ischemic LV dysfunction. In contrast, trials using in-scar injections of BMMNCs in patients with ischemic HF failed to show improved LV function.\(^{31,56}\) The reasons for these differences are not obvious; one possibility is the site of cell delivery, as in the study by Perin et al,\(^{46,47}\) cells were injected into the peri-infarct viable myocardium rather than into the scar itself.

In addition to the intramyocardial route, numerous studies have examined the effect of intracoronary infusion of BMMNCs in patients with HF, again with mixed results. A number of trials have reported an improvement in various parameters of LV function and anatomy.\(^{49,52,57}\) In the Transplantation of Progenitor Cells and Recovery of Left Ventricular Function In Patients With Nonischemic Dilative Cardiomyopathy (TOPCARE-CHD) study, Assmus et al\(^{50}\) compared the effects of intracoronary infusion of 22±11±10\(^6\) circulating EPCs or 205±110±10\(^6\) BMMNCs on global LV function in 75 patients with chronic ischemic cardiomyopathy. At 3 months after therapy, LVEF improved significantly in patients receiving BMMNCs (3.7±4.0 absolute ejection fraction units) but not in those receiving circulating EPCs (0.4±3.0 absolute EF units).\(^{50}\) This difference in response may be because of the functional impairment of circulating EPCs in patients with chronic HF,\(^{108}\) which limits their recruitment into the scar tissue, or it may reflect the contribution of cell types other than circulating EPCs. In the Transplantation of Progenitor Cells and Recovery of Left Ventricular Function In Patients With Nonischemic Dilative Cardiomyopathy registry, Assmus et al\(^{59}\) enrolled 121 patients with ischemic HF and reported a significant reduction of both N-terminal natriuretic peptide levels at 3 months.
probrinatriureticpeptideandN-terminalatrialnatriureticpeptideseum levels and a reduction in mortality at 3 months after intracoronary infusions of BMMNCs. However, other trials have failed to confirm the beneficial effects of intracoronary delivery of BMMNCs in HF. For example, when BMMNCs were given via intramycocardially or intracoronarily during CABG surgery, there was no improvement in regional or global LV function and no reduction in scar size.

BMMNCs have also been studied in the setting of nonischemic cardiomyopathy. In Transplantation of Progenitor Cells and Recovery of Left Ventricular Function in Patients With Nonischemic Dilatative Cardiomyopathy (TOPCARE-DCM), intracoronary infusion of $259 \pm 135 \times 10^6$ BMMNCs in 33 patients with dilated cardiomyopathy was associated with an improvement in regional contractile function and a decrease in N-terminal probrinatriuretic peptide serum levels, suggesting a beneficial effect on LV remodeling. Interestingly, the increase of regional contractile function was directly proportional to the functionality of the infused cells as measured by their colony-forming capacity.

In summary, studies of BMMNC administration in patients with chronic ischemic HF have yielded inconsistent results; all of these trials, however, have been small. Larger, phase II trials are needed to achieve definitive conclusions.

Mesenchymal Stem Cells

MSCs, also known as bone marrow stromal cells, are a subset of nonhematopoietic cells that are multipotent and plastic-adherent under culture conditions. MSCs can differentiate into chondrocytes, adipocytes, osteoblasts, and skeletal muscle cells and have also been reported to differentiate into cardiomyocytes and endothelial cells although this cardiogenic potential remains controversial. MSCs typically express CD105, CD73, CD90, and STRO-1 but lack hematopoietic markers (CD45, CD34, and CD14/CD11b).

The results of MSC administration in animal models of chronic HF have been encouraging. Direct epicardial injection of allogeneic MSCs in a dog model of ischemic HF induced by ameroid constriction resulted in differentiation of MSCs into smooth muscle cells and endothelial cells, increased vascularity, and improved myocardial function. Similarly, autologous MSCs, injected directly into a myocardial infarct scar, have been reported to attenuate LV remodeling and reduce infarct size in a swine model of ischemic cardiomyopathy. These data provided the groundwork for an ongoing randomized, double-blind, placebo-controlled study of autologous MSCs in patients with chronic ischemic LV dysfunction undergoing CABG (Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery [PROMETHEUS]; NCT00587990; Table 3). In rat models of both ischemic and nonischemic cardiomyopathy, intramyocardial injection of MSCs has been shown to improve cardiac function, increase angiogenesis, and reduce myocardial fibrosis. To date, the only clinical study that has examined the effects of MSCs in patients with HF is the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) trial by Hare et al, which compared 3 doses of autologous or allogeneic MSCs (20, 100, and $200 \times 10^6$ cells) in patients with ischemic cardiomyopathy and demonstrated that all doses favorably affected patient functional capacity, quality of life, and ventricular remodeling (Table 2).

HSCs and EPCs

HSCs reside in the bone marrow and differentiate into cells of both myeloid and lymphoid lineages. EPCs, on the other hand, are mobilized into peripheral blood in response to ischemic injury and promote neovascularization by differentiating into endothelial cells (re-endothelialization). CD34 is a typical surface marker of both HSCs and EPCs. Thus, CD34+ cells are found in the bone marrow and in the peripheral blood and have the potential to give rise to all blood cell types as well as endothelial cells (<1% of nucleated cells in the blood are CD34+).

Autologous CD34+ cell transplantation has been performed in patients with both ischemic and nonischemic cardiomyopathy. In the former setting, injection of CD34+ cells into the peri-infarct, viable LV regions during off-pump CABG surgery produced a greater improvement in contractile function than did CABG alone. Also, a small pilot study evaluating the safety and feasibility of intracoronary CD133+ or CD133−, CD34+ cell therapy in patients with old anterior MI reported a sustained improvement in regional perfusion and LV remodeling with both cell types. In the setting of nonischemic cardiomyopathy, a study by Vrtovec et al concluded that intracoronary infusion of CD34+ cells led to an increase in LVEF and 6-minute walk distance and a decrease in N-terminal probrinatriuretic peptide levels. Importantly, these beneficial effects were sustained during long-term follow-up. Another surface marker of HSCs and EPCs is CD133 (AC133). Stamm et al examined the effects of CD133+ cells, given by intramyocardial injection during CABG, in patients with ischemic HF. At 6 months after treatment, LVEF and perfusion of the infarcted myocardium increased to a greater extent in patients who received CABG and CD133+ therapy than in those who received CABG alone.

Recently, Perin et al investigated a novel population of hematopoietic cells, referred to as aldehyde dehydrogenase−bright cells, in 20 patients with ischemic HF (10 control and 10 treated). aldehyde dehydrogenase−bright cells, which have been isolated from human bone marrow and peripheral blood, express CD34, CD117, CD105, CD133, and CD166 and include primitive CD34+/CD38− cells. Transendocardial delivery of aldehyde dehydrogenase−bright cells produced a significant decrease in LV end-systolic volume at 6 months and a trend toward improved maximal oxygen consumption. In summary, the initial experience with CD34+ and CD133+ cells in HF (both of ischemic and nonischemic origin) is encouraging but limited by the small size of the trials. As is the case for other cells, larger studies will be necessary to evaluate the role of these cell types in the treatment of HF.

Adipose-Derived MSCs

Adipose tissue contains a pool of multipotent stem cells, designated as adipose-derived MSCs that are able to repopulate as undifferentiated cells, to develop as mature adipocytes, and to differentiate into other cell types along the mesenchymal lineage. Reports that adipose-derived MSCs can differentiate into cardiomyocytes and endothelial cells have motivated studies in animal models of HF. Using a cell sheet technology, Miyahara et al reported that...
transplantation of monolayered MSCs into scarred myocardium reversed wall thinning in the scar area and improved cardiac function. In another study, the effects of transplanting undifferentiated or cardiac predifferentiated adipose-derived MSCs were compared with those of BMMNCs in a rat model of chronic MI. One month after transplantation, adipose-derived MSCs induced an improvement in LVEF, an increase in angiogenesis, and a decrease in fibrosis that were significantly greater than those effected by adipose-derived cardiomyogenic cells or BMMNCs. Additionally, intramyocardial injection of adipose stem cells at 1 week after coronary occlusion has been reported to mitigate the deterioration in cardiac contractile function and enhance angiogenesis in infarcted rat hearts.

In the clinical arena, no full report of adipose-derived MSCs in HF is available yet. The preliminary results of the A Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium (PRECISE) trial by Perin et al. in 27 patients indicate that administration of adipose-derived cells resulted in stabilization of infarct size and improvement in maximal oxygen consumption.

### Table 3. Ongoing Clinical Trials of Stem Cell Therapy in Heart Failure Registered at clinicaltrials.gov (April 2013)

<table>
<thead>
<tr>
<th>Trial Design Phase and Title</th>
<th>Cell Type</th>
<th>Status</th>
<th>Design</th>
<th>Estimated Patient Enrollment</th>
<th>Delivery Method</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I/II; Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)</td>
<td>Autologous MSCs</td>
<td>Active, not recruiting</td>
<td>Randomized, double-blind, placebo-controlled study</td>
<td>45</td>
<td>Intramyocardial</td>
<td>NCT00587990</td>
</tr>
<tr>
<td>Phase I/II; The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)</td>
<td>Autologous hMSC or hBMC</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo-controlled study</td>
<td>67</td>
<td>Intramyocardial (transendocardial)</td>
<td>NCT00786066</td>
</tr>
<tr>
<td>Phase I/II; The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (POSEIDON-DCM)</td>
<td>Autologous MSCs Allogenic MSCs</td>
<td>Recruiting</td>
<td>Randomized, open-label, pilot study</td>
<td>36</td>
<td>Intramyocardial (transendocardial)</td>
<td>NCT01392625</td>
</tr>
<tr>
<td>Phase I; Autologous Mesenchymal Stromal Cell Therapy in Heart Failure</td>
<td>Mesenchymal stromal cells</td>
<td>Recruiting</td>
<td>Randomized controlled study</td>
<td>60</td>
<td>Intramyocardial</td>
<td>NCT00644410</td>
</tr>
<tr>
<td>Phase II; A Phase II Dose-Escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Heart Failure (REVASCOR)</td>
<td>Mesenchymal precursor cells</td>
<td>Active, not recruiting</td>
<td>Dose-escalation study</td>
<td>60</td>
<td>Intramyocardial (transendocardial)</td>
<td>NCT00721045</td>
</tr>
<tr>
<td>Phase II; Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy (NOGA-DCM)</td>
<td>Autologous BM-HSCs (CD34+ cells)</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo-controlled study</td>
<td>60</td>
<td>Intramyocardial</td>
<td>NCT01350310</td>
</tr>
<tr>
<td>Phase I; Cardiac stem cell infusion in patients with ischaemic cardiomyopathy (SCIPIO)</td>
<td>c-kit+ cardiac progenitor cells</td>
<td>Active, not recruiting</td>
<td>Randomized, open-label study</td>
<td>33</td>
<td>Intracoronary</td>
<td>NCT00474461</td>
</tr>
<tr>
<td>Phase II; Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR)</td>
<td>Cardiosphere-derived cells</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo-controlled study</td>
<td>274</td>
<td>Intracoronary</td>
<td>NCT01458405</td>
</tr>
<tr>
<td>Phase II; Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure (CHART-1)</td>
<td>Bone marrow-derived mesenchymal cardiopoietic cells (C3BS-CQR-1)</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo-controlled study</td>
<td>240</td>
<td>Intramyocardial</td>
<td>NCT01768702</td>
</tr>
<tr>
<td>Phase II; An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (ixCELL DCM)</td>
<td>Bone marrow-derived cells, including primarily CD90+ MSCs, CD14+ monocytes and alternatively activated macrophages</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo-controlled study</td>
<td>108</td>
<td>Intramyocardial (transendocardial)</td>
<td>NCT01670981</td>
</tr>
</tbody>
</table>

BMC indicates bone marrow cell; BMMNC, bone marrow mononuclear cell; CSC, cardiac stem cell; hBMC, human bone marrow cell; hMSC, human mesenchymal stem cell; and MSC, mesenchymal stem cell.

### Cardiac Stem Cells
One of the most dramatic developments in the history of cardiac biology has been the recent recognition that the adult heart...
undergoes a continuous turnover of its cellular components (including myocytes).\textsuperscript{124} This process is thought to be underlain by a population of resident stem cells that possess the capacity to differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells\textsuperscript{124} (Figure 2). The discovery that the heart is a self-renewing organ has not only refuted the long-held doctrine that the myocardium is a postmitotic tissue (composed of cells that have withdrawn from the cell cycle and are terminally differentiated) but has also opened exciting therapeutic avenues.

\textbf{c-Kit+ CSCs}

In 2003, Beltrami et al\textsuperscript{125} described a population of cells isolated from the adult rat heart that expressed the tyrosine kinase receptor c-kit (a marker of stemness) but lacked any markers of hematopoietic lineage. These c-kit+ CSCs were shown to be self-renewing, clonogenic, and multipotent, exhibiting the ability to differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells both in vitro and in vivo.\textsuperscript{125–127} Four years later, a similar population of c-kit+ CSCs were identified in the adult human heart.\textsuperscript{123} Injection of human CSCs into infarcted rodent myocardium resulted in improvement of LV function and structure and formation of a chimeric heart that contained human myocardium composed of myocytes and coronary vessels.\textsuperscript{127}

In the past decade, the ability of human and rodent CSCs to alleviate LV dysfunction and remodeling and promote regeneration has been repeatedly demonstrated by several laboratories in various preclinical animal models of acute MI.\textsuperscript{126,128–131} Evidence that ischemic cardiomyopathy is associated with loss of functionally competent CSCs\textsuperscript{132} has ignited interest in investigating the effects of CSCs in the setting of chronic HF as well. Intramyocardial injection of c-kit+ CSCs at the borders of an infarct 20 days after a permanent coronary occlusion in rats was reported to result in replacement of \(\approx 42\%\) of the scar with new myocardium, attenuation of LV dilation, and preservation of LV function.\textsuperscript{26} However, in contemporary medicine, most infarcts are reperfused. Furthermore, from a practical standpoint, the technique most conducive to widespread use of CSCs in patients with HF would be intracoronary delivery. To address these issues, Tang et al\textsuperscript{28} investigated whether administration of CSCs is effective in regenerating cardiac tissue and alleviating postinfarction LV remodeling and dysfunction when these cells are infused intracoronarily in the setting of an old MI produced by a temporary coronary occlusion followed by reperfusion. One month after coronary occlusion/reperfusion, rats received an intracoronary infusion of vehicle or enhanced green fluorescent protein-labeled (EGFP) CSCs. Thirty-five days later, CSC-treated rats exhibited more viable myocardium in the risk region, less fibrosis in the noninfarcted region, and improved LV function.\textsuperscript{28} However, the number of enhanced green fluorescent protein+ cells expressing markers of cardiogenic commitment was too small to account for the augmentation of LV function (enhanced green fluorescent protein+ cells accounted for only 2.6±1.1\% of the region at risk and 1.1±0.4\% in the noninfarcted region). These observations suggest that an important mechanism whereby CSCs produced their salutary effects was the secretion of cytokines/growth factors that exerted paracrine actions on endogenous cells, particularly endogenous CSCs, which in turn proliferated and differentiated into adult cardiac cells. In support of this hypothesis was the finding that the pool of endogenous CSCs expanded to a greater degree in CSC-treated than in control rats.\textsuperscript{28}

The efficacy of CSCs in chronic ischemic cardiomyopathy,\textsuperscript{26,28} was surprising, as a scar would seem to be a very hostile environment to the homing and survival of transplanted cells, and the signals (adhesion molecules and growth factors) that attract and activate CSCs soon after ischemia-reperfusion would be expected to have largely abated once the healing process is complete. To verify these rat findings\textsuperscript{26,28} in a large, clinically relevant species, a similar study was performed in pigs that underwent a 90-minute coronary occlusion followed by reperfusion.\textsuperscript{30} At the time of occlusion, the right atrial appendage was harvested for isolation and expansion of c-kit+ CSCs; 3 months after MI, 1 million autologous CSCs were infused into the infarct-related artery using a balloon catheter. Similar to the results obtained in rats, a month later the pigs treated with CSCs exhibited an increase in LVEF and systolic thickening fraction in the infarcted LV wall, as well as a decrease in LV end-diastolic pressure and an increase in LV dP/dt max.\textsuperscript{30} The encouraging results of these studies of intracoronary CSC infusion in the setting of an old MI\textsuperscript{28,30} laid the groundwork for Cardiac Stem Cell Infusion in Patients with Ischemic Cardiomyopathy (SCIPIO), the first clinical trial of CSCs (Figure 1).

SCIPIO was a phase I, randomized, open-label trial of autologous CSCs for the treatment of ischemic HF. The target population consisted of patients with LVEF \(\leq 40\%\) who underwent CABG. Approximately 4 months after CABG, 1 million autologous CSCs (isolated and expanded from myocardial tissue harvested during surgery) were administered by intracoronary infusion; controls were not given any treatment. Although the 2-year follow-up has not been completed, the interim results are very encouraging.\textsuperscript{67,133} In 20 CSC-treated patients, LVEF (measured by 3-dimensional echo) increased from 29.0±1.7\% before CSC infusion to 36.0±2.5\% at 4 months after infusion. By contrast, in 13 control subjects, LVEF did not change. The salutary effects of CSCs persisted and, if anything, became even more pronounced at 1 year (LVEF: +8.1\% versus baseline; \(n=17\)) and 2 years (LVEF: +12.9\%; \(n=8\)).\textsuperscript{134} In 9 CSC-treated patients in which MRI could be performed, there was a profound reduction in infarct size at 4 months (from 34.9±2.3 to 21.6±2.7 g \([-38.1\%]\)) and even more at 1 year (from 33.9±3.0 to 18.7±3.6 g \([-44.8\%]\]).\textsuperscript{67} These salutary effects were associated with a significant improvement in the NYHA functional class and in the quality of life (measured by the Minnesota Living with Heart Failure Questionnaire). Aside from the setting of ischemic cardiomyopathy, CSCs have also been found to exert salutary effects in a rat model of anthracycline-induced cardiomyopathy.\textsuperscript{135}

In summary, several studies have documented the ability of CSCs to promote regeneration and alleviate LV dysfunction and remodeling in various preclinical models of post-MI cardiomyopathy. The results of the first clinical trial (SCIPIO) are consistent with this preclinical work and suggest that intracoronary infusion of autologous CSCs results in a substantial and sustained improvement in LV systolic function, in a
Cardiospheres and Cardiosphere-Derived Cells

Cardiospheres were first described by Messina et al\textsuperscript{137} in 2004. Using subcultures of atrial or ventricular human biopsy samples and murine hearts, these authors isolated a population of cells that grew as self-adherent clusters and could differentiate into cardiomyocytes, endothelial cells, and smooth muscle cells. Messina et al\textsuperscript{137} termed these clusters cardiospheres. Three years later, Smith et al\textsuperscript{138} presented a method in which cardiospheres obtained from percutaneous endomyocardial biopsy specimens were plated to yield cardiosphere-derived cells (CDCs). These CDCs were reported to differentiate into electrically stable cardiomyocytes in vitro and, when injected into a murine infarct model, to promote cardiac regeneration and improved cardiac function.\textsuperscript{139} In 2009, Johnston et al\textsuperscript{27} reported that intracoronary delivery of human CDCs in pigs with old MI resulted in cardiac regeneration, reduction in relative infarct size, attenuation of adverse LV remodeling, and improvement in cardiac function. Phenotypically, cardiospheres and CDCs are a heterogeneous mixture of many different cell types, including cells that express endothelial (kinase insert domain receptor [KDR] [human]/flk-1 [mouse], CD31), stem cell (CD34, c-kit, Sca-1), and mesenchymal (CD105, CD90) antigenic markers (Figure 2).\textsuperscript{137} Which of these cells type(s) is responsible for the observed effects on cardiac function and remodeling is unknown. In Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction (CADUCEUS), 98% of CDCs infused were positive for CD105, suggesting a mesenchymal nature.\textsuperscript{68} In a recent study by the same group,\textsuperscript{29} the safety and efficacy of direct intramyocardial injection of CDCs and cardiospheres were compared in a porcine model of post-MI HF; although CDCs and cardiospheres had equivalent effects on LVEF, the latter were superior in improving hemodynamics and regional function and in mitigating ventricular remodeling. The enhanced potency of cardiospheres for myocardial repair has been attributed to enhanced stemness and cell–matrix interactions.\textsuperscript{139}

This preclinical work was translated by Makkar et al\textsuperscript{68} into a phase I, randomized trial (CADUCEUS) in patients with a recent MI and an LVEF≤45% but ≥25%. At 1.5 to 3 months after MI, 17 patients received an intracoronary infusion of escalating doses of autologous CDCs (12.5, 17.3, or 25 million cells), which were produced from an endomyocardial biopsy. (However, the amount of tissue used to produce CDCs was reported to be 276 mg [SD, 177; range, 93–891 mg],\textsuperscript{68} which is all but impossible to obtain with endomyocardial biopsies). Eight control patients received standard care. In 2 patients, CDCs were found to be aneuploid (trisomy 8) and had to be discarded. At 12 months of follow-up, CDC-treated patients exhibited a 42% reduction in scar size (from 24% to 12% of the LV), concomitant with an increase in viable tissue and regional systolic wall thickening in the infarcted region. However, CDC therapy failed to increase LVEF, reduce LV volumes, and improve NYHA functional class or quality of life as assessed with the Minnesota Living with Heart Failure Questionnaire.\textsuperscript{68} Although the increase in nongadolinium enhanced tissue in CDC-treated patients was claimed to be proof of cardiac regeneration,\textsuperscript{68} it could also be accounted for by other changes unrelated to regeneration, such as hypertrophy, decreased interstitial space, reduced vascular permeability, and improved perfusion.\textsuperscript{140-144}

In summary, CDCs are a mixture of different cell types (predominantly expressing mesenchymal markers) that have been reported to promote regeneration and alleviate post-MI dysfunction and remodeling in various preclinical models.\textsuperscript{27,29,138,145,146} The clinical effects of CDCs are unclear. The MRI data reported in CADUCEUS are consistent with regeneration (but they do not prove it); however, evidence that CDCs have beneficial effects on global LV function and clinical status is still lacking. Given the heterogeneous nature of this cell preparation, it will be difficult to identify which component(s) accounts for the salubrious effects. As is the case of c-kit+ CSCs, larger phase II studies are needed to evaluate the therapeutic potential of CDCs.

Other Cardiac Progenitor Cells

Sca-1+ CSCs. The existence of Sca-1+ progenitors in the adult mouse heart was reported by Oh et al.\textsuperscript{147} These cells expressed CD31 and cardiogenic transcription factors (GATA-4, MEFC2, and MEF-1) but lacked blood lineage markers, c-kit, Flt-1, Flk-1, vascular endothelial cadherin, von Willebrand factor, and HSC markers (CD45 and CD34).\textsuperscript{147} In vitro, Sca-1+ cells have the ability to express cardiac structural genes and differentiate into beating cardiomyocytes on treatment with 5-azacytidine\textsuperscript{147} and oxytocin.\textsuperscript{148} Transplantation of Sca-1+ cells into the peri-infarct and infarct zones in a murine model of MI resulted in endothelial and cardiomyogenic differentiation of these cells with attenuation of LV remodeling.\textsuperscript{149} However, the effects of these cells in the setting of chronic HF remain to be determined; furthermore, the lack of a human homolog of Sca-1 makes translation difficult.

Side Population Cells. The so-called side population cells are characterized by their ability to exclude the Hoechst 33342 dye via the ATP-binding transporters breast cancer resistance protein/ATP-binding cassette sub-family G member 2 (Bcrp1/Abcg2) and multidrug resistance protein 1 (MDR1).\textsuperscript{150} First identified in murine bone marrow as HSCs,\textsuperscript{151} side population cells were subsequently isolated by Martin et al\textsuperscript{152} from adult as well as embryonic mouse hearts and characterized as CD31-, Sca-1\textsuperscript{high}, c-kit\textsuperscript{low}, CD34\textsuperscript{low}, and CD45\textsuperscript{low}. Although cardiac side population cells have been reported to differentiate into mature cardiomyocytes, endothelial cells, and smooth muscle cells and to regenerate cryoinjured myocardium,\textsuperscript{153} their ability to induce cardiac repair has not been tested.

Islet-1+ Cells. During cardiogenesis, Isl-1+ cells give rise to cardiac muscle, the conduction system, and endothelial and smooth muscle cells in the heart compartments.\textsuperscript{154} Laugwitz et al\textsuperscript{155} proposed that Isl-1+ cells represent endogenous cardiac progenitors that display conversion to a mature cardiac phenotype, with intact calcium dynamics and action potentials;\textsuperscript{155} however, the ability of these cells to repair...
injured myocardium in vivo has never been demonstrated. Importantly, these cells do not exist in the postnatal ventricular myocardium, either under normal conditions or after MI, making it unlikely that they serve as cardiac progenitors or will have any clinical application.156

Potential Mechanisms of Actions of Stem Cells in HF

Taken together, the studies reviewed above (Tables 1 and 2) suggest that at least some types of cell therapy are likely to improve cardiac function in chronic HF. What remains largely unknown, however, is the mechanism(s) responsible for these beneficial effects. Here, we discuss briefly the various hypotheses that have been proposed (Figure 3).

(Trans)differentiation of Transplanted Cells Into Cardiac Cells

Although this may seem the most obvious explanation for the salubrious effects of stem cells, the evidence obtained thus far does not support (trans)differentiation of transplanted cells as the only, or even the major, mechanism of action. As mentioned earlier, Reinecke et al157 found that transplanted skeletal myoblasts differentiate into skeletal muscle fibers and do not express cardiac-specific genes. Transdifferentiation of bone marrow cells into cardiac myocytes remains highly controversial, with studies both supporting3,15,158 and refuting105,106 this concept. Others have suggested fusion of bone marrow cells with resident cardiomyocytes as the responsible mechanism,159,160 but this has also been refuted161,162. Similarly, transdifferentiation of human peripheral blood CD34+ cells into cardiomyocytes and vascular smooth muscle cells remains controversial.163,164 Although the therapeutic benefits of MSCs have been ascribed to differentiation toward cardiac and vascular lineages,18,110,111,165 most studies have not supported this concept, suggesting instead that the major actions of MSCs are paracrine.166–168

A similar uncertainty applies to cardiac-derived cells. As discussed above, CSCs are multipotent, being able to differentiate into myocytes, endothelial cells, and vascular smooth muscle cells in vitro.158 When transplanted in injured hearts, CSCs give rise to vascular cells and to cells that express myocyte-specific proteins (although these cells are usually small and do not resemble adult myocytes).26,28,30,128,131 In some studies, particularly in models of acute MI, the magnitude of this regenerative process has been found to be substantial.125,126,169,170 However, in a rat26 and pig30 model of chronic post-MI HF, differentiation of transplanted CSCs into myocytes or myocyte-like cells was quantitatively insufficient to account for the improvement in LV function. In the case of CDCs, differentiation into cardiac cells has been reported to be either a minor mechanism of action171 or nonexistent.172,173

In summary, differentiation of transplanted cells along the cardiac lineage may occur. However, the key issue is the magnitude of this phenomenon vis-à-vis the improvement in function. In most of the studies reported to date, the functional benefits seem to be disproportionate to the relatively small number of new cardiac cells formed by differentiation of transplanted cells; consequently, the former cannot be accounted for solely by the latter. Other mechanisms must be at work.

Formation of New Blood Vessels From Transplanted Cells

Differentiation of transplanted cells into new blood vessels has been reported with various cells (eg, MSCs,19 adipose-derived cells,174,175 CD34+ cells,176,177 and CSCs).125,178 Experimentally, this phenomenon may be important in models of chronic coronary occlusion, which can be associated with the presence of ischemic but viable myocardium,125,126,169,170 but not in models...
in which the artery that supplies the infarcted/scarred myocardium is patent. Clinically, formation of new vessels may contribute to improved cardiac performance in some patients with ischemic heart disease, but it is difficult to envision how it could do so in the setting of nonischemic cardiomyopathy or in patients with ischemic heart disease who do not have flow-limiting coronary lesions (eg, revascularized patients).

**Paracrine Mechanisms**

The inability to explain the salutary effects of transplanted stem cells on the basis of their differentiation has led to the paracrine hypothesis, that is, the concept that transplanted cells induce myocardial repair by releasing signals (cytokines, chemokines, growth factors, possibly exosomes or microparticles) into the surrounding tissue, which in turn promote a number of restorative processes including activation of endogenous CSCs, neovascularization, inhibition of apoptosis, inhibition of hypertrophy, and favorable alterations of the ECM. Collectively, these actions result in enhanced LV function, improved perfusion, and myocardial repair.

1. **Activation of endogenous CSCs:** In the aforementioned study by Tang et al in a rat model of chronic HF, infusion of exogenous CSCs was found to promote proliferation of endogenous CSCs in both the infarcted and noninfarcted regions, suggesting that activation of the endogenous pool of CSCs via paracrine mechanisms was a major mechanism of benefit. It is known that CSCs secrete growth factors (such as hepatocyte growth factor and insulin growth factor-1) that stimulate other CSCs to migrate through the myocardial interstitium, proliferate, and differentiate into myocytes and vascular structures. Activation of endogenous CSCs has also been suggested to be an important mechanism underlying the beneficial effects of other cell types, including MSCs.

2. **Induction of neovascularization:** Many stem cells can induce neovascularization by secreting chemokines (stromal cell–derived factor-1) and proangiogenic factors (vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, insulin growth factor-I, tissue growth factor-β, and angiopoietin-1). EPCs recruited to the ischemic area can also secrete the endothelial and inducible isoforms of nitric oxide synthase and promote proliferation of endothelial cells. The resulting neovascularization may improve blood supply to the viable cells that remain in the infarcted region and thus improve cardiac function in settings of chronic coronary occlusion; as mentioned above, however, this mechanism would not account for improved function in experimental models of reperfused infarction, where no residual ischemia is present, or in patients without persistent ischemia.

3. **Inhibition of apoptosis:** A number of studies suggest that paracrine factors (such as insulin growth factor-1 released by stem cells after transplantation inhibit cardiomyocyte death by apoptosis). In vitro and in vivo data in models of acute MI suggest that Akt overexpressing MSCs decrease cardiomyocyte apoptosis. Combined transplantation of skeletal myoblasts and AC133+ cells was also reported to improve cardiac function by reducing myocardial apoptosis.

4. **Inhibition of hypertrophy:** Administration of stem cells in models of HF is associated with a reduction in the hypertrophic response of surviving myocytes. It remains uncertain, however, whether this is a primary action of transplanted cells or it is secondary to improved cardiac performance.

5. **Remodeling of the ECM:** Stem cells can modulate various constituents of the ECM, thereby limiting infarct expansion, LV remodeling, and myocardial fibrosis. Skeletal myoblasts have been reported to preserve matrix collagen architecture, to reduce fibrosis in the peri-infarct and infarct-remote regions, and to modulate MMP-2 and tissue inhibitors of MMP-4 levels, suggesting a favorable effect on the ECM metabolism. The importance of ECM alterations in CSC-dependent repair is underscored by the findings of Rota et al, who reported that CSCs increased MMP-2, MMP-9, and MMP-14 levels and decreased tissue inhibitors of MMP-4 levels in a rat model of post-MI HF.

**Cell Fusion**

In 2004, spontaneous cell fusion was proposed as an alternative mechanism by which transplanted bone marrow cells produce apparent regeneration of various adult tissues. This concept was based on work by Alvarez-Dolado et al, who used a method based on Cre-Lox recombination for detecting cell fusion events of bone marrow cells with cardiomyocytes. Subsequent studies, however, concluded that c-kit+ bone marrow cells differentiated into myocytes and coronary vessels independent of cell fusion. The use of Cre-Lox recombination as an appropriate model to study cell fusion has been challenged because the unmodified Cre-recombinase in the progenitor cells can cross the membrane of the recipient cell, mimicking cell fusion. The notion that cell fusion is an important mechanism underlying the salubrious effects of stem cells has lost support in recent years.

**Current Challenges, Unresolved Issues, and Future Directions**

Taken together, the preclinical and clinical work performed to date suggests that administration of stem cells has considerable potential to improve cardiac function and regenerate viable myocardium in HF. Despite these encouraging results, however, no cell type has been conclusively demonstrated to be effective in alleviating HF in patients. It is clear that to unleash the full potential of cell-based therapies and proceed toward clinical translation, a number of major unresolved issues will have to be resolved; for example, what are the optimal cell type(s), the optimal cell dose, the optimal route of cell administration, and the optimal frequency of treatment? These questions can be answered only by performing careful preclinical and clinical studies.

Unfortunately, the current environment does not support studies that compare cells, doses, routes of administration, and frequency of treatment. At the preclinical level, this type of work is likely to receive low-priority scores by peer review groups because it is, by definition, descriptive and lacks mechanistic insights and conceptual novelty. In the clinical arena, comparisons of different cell types or doses are expensive and time-consuming. It is hoped that sponsors and funding...
agencies will recognize that this type of research is indispensable to translate cell-based therapies to humans and will identify it as a priority for funding.

Cell Type

It is unknown which, among the many different types of stem/progenitor cells that have been studied to date (Tables 1 and 2), is most effective in a given pathophysiological setting. Despite the obvious importance of this question, very few studies have directly compared different cell types with respect to the outcomes of therapy.\textsuperscript{25,101,107,185} Such studies are difficult because they require that the dose–response relationships for each cell type be defined and compared (as simply comparing one dose of cells would be inadequate). This has not been done heretofore. For example, the claim that CDCs are superior to CSCs is untenable because it is predicated on the use of 1 dose of cells.\textsuperscript{185} Similarly, the few studies that have compared different cell types\textsuperscript{25,101,107} have not evaluated the dose–response relationships for each cell type.

A related and unresolved issue is whether combinations of different cell types may be more efficacious than a single-cell type. Theoretical considerations, as well as preclinical studies of BMMNCs, skeletal myoblasts,\textsuperscript{100,186,187} MSCs, and CSCs,\textsuperscript{188} suggest that the former approach may offer advantages because the actions of different cells may be complementary or even synergistic.\textsuperscript{188}

Cell Dose

It is evident from Tables 1 and 2 that the doses of cells used to treat chronic HF have varied enormously. Although it seems obvious that the effects of cell-based therapies will depend on the number of cells administered, the nature of this relationship is still unknown for most cell types. In the clinical realm, only 2 studies have addressed the dose dependency of the effects of stem cells in HF. In the MAGIC trial,\textsuperscript{42} a higher dose (8x10^6) of skeletal myoblasts was more effective in decreasing LV volumes and reversing LV remodeling than a low dose (4x10^5), although neither dose improved LV function. In the POSEIDON trial, Hare et al\textsuperscript{59} compared 3 doses of autologous or allogeneic MSCs (20, 100, and 200x10^6 cells) in patients with ischemic cardiomyopathy and demonstrated that all doses favorably affected patient functional capacity, quality of life, and ventricular remodeling, although 200x10^6 cells were (unexpectedly) less effective than 20x10^5 cells. These results differ from those obtained by these investigators in a swine model of ischemic cardiomyopathy, in which both a high dose (200x10^6 cells) and a low dose (20x10^6 cells) of MSCs increased regional function, but only the high dose effected reverse remodeling.\textsuperscript{24} To address this important issue, an ongoing phase II dose-escalation study (A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells [MPCs] in Subjects With Heart Failure [REVASCOR]) is assessing the feasibility and safety of transendocardial delivery of 3 doses of allogeneic mesenchymal precursor cells (25, 75, 150x10^6 cells) in patients with HF (NCT00721045; Table 3). Similar studies of the dose–response relationship are needed for other cell types.

Route of Administration

As is the case for the optimal cell type and dose, the most effective technique to deliver cells to the heart is still unknown. The major routes used to date are direct injection into the LV wall (transendocardially or transepicardially) and intracoronary infusion. Transepicardial injection is performed during cardiac surgery\textsuperscript{15,42}; this method offers direct visualization of the scarred regions but is limited by the requirement for surgery. With transendocardial injection, cells can be delivered directly into the LV wall by using an injection catheter advanced across the aortic valve and positioned against the endocardial surface. The advantages of this technique over intracoronary infusion are that (1) electromechanical mapping of the endocardial surface with a NOGA system can be used to trace viable, ischemic, and scarred myocardium, thereby enabling targeted injection of cells into the scar or into the border zone, and (2) cells can be delivered to a scarred region even if the coronary artery supplying it is totally occluded. Because of these advantages, transendocardial injection has been used extensively in the clinical arena.\textsuperscript{12,14,56,43,47,54,58} However, intramyocardial injections may disrupt tissue architecture and create cell clumps that lack adequate blood supply, resulting in cell death. Furthermore, the distribution of cells within the infarcted region is usually inhomogeneous.\textsuperscript{131,189}

Intracoronary delivery involves the infusion of cells into a coronary artery, usually during a brief coronary occlusion produced by inflating a balloon at the tip of the catheter. The rationale for stopping flow is to prevent the rapid washout of the cells and to facilitate their extravasation into the interstitium. Compared with transendocardial injection, intracoronary delivery offers several advantages: (1) it results in a much more uniform distribution of cells within the infarcted region,\textsuperscript{131} (2) it does not require specialized training or the purchase of specialized equipment, and (3) it is technically easier, and therefore more practical for widespread use in clinical practice. The widespread distribution of cells within the infused vascular bed has also the theoretical advantage of enabling them to decide where to go in response to local cues. However, intracoronary delivery has also certain disadvantages versus transendocardial injection: (1) the immediate retention of cells is lower\textsuperscript{190,191} (eg, 2.6±0.3% after intracoronary infusion compared with 11±3% after intramyocardial injection),\textsuperscript{192} presumably because of rapid washout of cells, (2) microvascular occlusion can occur when large cells such as MSCs (10–20 µm),\textsuperscript{193,194} skeletal myoblasts (≈20 µm),\textsuperscript{195} and CDCs (≈21 µm)\textsuperscript{27,137,139} are infused (this problem is not encountered when smaller cells, such as CSCs and BMMNCs, are used), and (3) delivery of cells to a myocardial region supplied by an occluded artery is not possible.

To date, relatively few studies have compared different routes of cell delivery,\textsuperscript{12,14,56,131,191,194,196–198} with discrepant results. None of them has used a range of doses, which, as discussed above, is necessary to achieve valid conclusions. Comparisons of the intracoronary and transendocardial delivery routes in large animal models using a range of doses of cells are needed to resolve this issue.

Frequency of Administration

There is no a priori reason to posit that the effects of a single-cell administration cannot be improved by a repeated...
administration. Most stem cells can be frozen, stored, and reused at a later time. Consequently, it seems rather curious that almost every study performed heretofore has used a single injection of cells to determine whether this therapy is efficacious in HF. This would be tantamount to determining the effect of an antibiotic on an infectious disease by giving only 1 dose. The lack of studies evaluating repeated cell injections is all the more perplexing when one considers that there is evidence suggesting a dose–dependent–response relationship between number of cells injected and functional benefit, as discussed above. The effects of stem cells in HF patients should not be labeled as negative, modest, or small on the basis of the results obtained with a single treatment; in our opinion, the effects of repeated administrations of stem cells need to be compared with those of a single administration, lest a cell therapy may be inappropriately dismissed as ineffective.

The few available data do support the concept that repeated injections of cells are more efficacious than a single injection. In animal models of old MI, repeated injections of skeletal myoblasts were more effective than single injections in increasing LV EF and vasculogenesis and in decreasing fibrosis. Clearly, further studies are necessary to determine the relationship between the number/frequency of cells administered and their effects on cardiac function.

Although it is appreciated that the issues discussed above (items 1–5) are not conceptually challenging, it is our opinion that they have enormous practical importance and need to be addressed. It is unlikely that optimal clinical application of cell therapy will be achieved until we have an answer to these questions.

Cell Retention, Survival, Long-Term Engraftment, and Lineage Commitment

Stem cell studies have consistently shown very low rates of long-term cell engraftment: regardless of cell type, dose, and mode of delivery, >90% of injected cells disappear in the first few days and <2% can still be found 4 weeks after transplantation. This massive cell loss is the result of 2 sequentially distinct events. During or immediately after delivery, there is significant loss attributable to failure of cells to extravasate (intracoronary infusion) or leakage through transcapillary/transendocardial puncture holes coupled with removal through the venous system (intramyocardial injection). For example, in the acute phase of MI, only ≈10% of CSCs and <10% of MSCs were found in the myocardium 24 hours after intramyocardial injection in mice and only 2% to 5% of BMMNCs a few hours after intracoronary infusion in humans. In a porcine model of cardiopulmonary bypass, only 10% of epicardially injected microspheres approximating the size of MSCs were retained within the sites of injection after 30 minutes. Then, during the first weeks after transplantation, most of the cells that were initially retained die because of ischemia caused by poor vascularization of the injected region, inflammation with attendant oxidative stress and release of cytotoxic cytokines, immune destruction of allogeneic cells, and apoptosis after disengagement of anchorage-dependent cells from their ECM (anoikis).

Clearly, the massive loss of transplanted cells is a major unresolved problem that limits the efficacy of any type of cell therapy. Improving cell homing, survival, and engraftment in the hostile ischemic environment is therefore important for optimizing therapeutic benefits. Several strategies are currently under investigation, including pretreatment of the target tissue, ex vivo pretreatment of cells (genetic modifications, physical or pharmacological preconditioning), and implantation of cells included in scaffolds made of biocompatible matrix. Pretreatment of the host tissue has been accomplished with ultrasound-mediated destruction of microbubbles in the coronary circulation (which improves recruitment of BMMNCs and MSCs, probably by creating capillary pores and extracorporeal shock wave treatment (which has shown benefit in patients with ischemic HF receiving intracoronary BMMNCs in the Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium [CELLWAVE] trial). Concerning ex vivo pretreatment of stem cells, many promising strategies have emerged. One is the overexpression of antiapoptotic genes, such as heme oxygenase-1 (HO-1), B-cell lymphoma 2 (Bcl-2) Akt, or proto-oncogene serine/threonine-protein kinase (Pim-1), which has been shown to increase the survival and function of MSCs and CSCs including their capacity to secrete paracrine mediators. Augmenting either the expression of stromal cell–derived factor-1 in the myocardium or that of its receptor, chemokine receptor type 4 (CXCR4), on stem cells increases cell recruitment. Preconditioning EPCs with antibodies, high mobility group box-1 (HMGB-1), or small molecules increases their neovascularization capacity by activating β2 integrins. Similarly, preconditioning human EPCs and BMMNCs with the endothelial nitric oxide synthase transcription enhancer AVE9488 improves their migratory and neovascularization potential. Many studies have found that preconditioning MSCs and EPCs with simulated ischemia upregulates prosurvival, angiogenic, and migratory proteins, such as hypoxia inducible factor-1α (HIF-1α), Akt-1, Bcl-2, angiopoietin-1 (Ang-1), vascular endothelial growth factor, as well as the receptors CXCR4 and c-Met, and imparts beneficial effects. Preconditioning human CSCs with the HO-1 inducer cobalt protoporphyrin (CoPP) significantly enhances their resistance to apoptosis.

The importance of promoting the lineage commitment of transplanted cells is illustrated by the recently reported Cardiopietic stem cell therapy in heart failure (C-CURE) trial, in which lineage specification of MSCs was achieved by exposing them to a cardiogenic cocktail regimen that triggered expression and nuclear translocation of cardiac transcription factors; in this study, administration of autologous bone marrow–derived mesenchymal cardiopoietic cells was found to effect favorable LV remodeling and improve cardiac function in patients with ischemic HF. Embedding cells in natural (eg, matrigel, collagen, fibrin, alginate) or synthetic (eg, peptide nanofibers) biomaterials is another means of enhancing stem cell function. Biomaterials promote cell engraftment, retention, and differentiation because of their low viscosity and their similarity to myocardial ECM, which preserves cell-to-matrix signals. The 2 main approaches in cardiac tissue engineering are in vitro engineering, which consists of seeding cells on preformed porous scaffolds that are cultivated in vitro and then applied on the
epicardial surface, and in vivo engineering, in which a mixture of biomaterials and cells is injected and the formation of a bicomplex occurs in situ. Conceptually, biomaterials could be designed to release growth factors in a controlled manner that promotes survival and engraftment of cells, and also guides cell phenotype decisions.

In summary, improving cell survival and engraftment is crucial to the progress of cell therapy and thus should be a high-priority area for research. The strategies summarized above (pretreatment of target tissue, pretreatment of cells, embedding cells in a matrix) are not mutually exclusive and may have additive or even synergistic effects.

Ongoing Clinical Trials
At the time of this writing, ClinicalTrials.gov lists 10 clinical trials that are testing the safety and efficacy of stem cells in patients with HF (Table 3). To evaluate the effects of intramyocardial injection of BMMNCs and MSCs in patients with ischemic cardiomyopathy, 3 phase I/II randomized, double-blind, placebo-controlled trials are being performed at the University of Miami. The primary end point of PROMETHEUS is to test the safety of intramyocardial injection of autologous human MSCs in patients with chronic MI undergoing CABG. The Transendocardial Autologous Cells (human MSCs or human bone marrow cells) in Ischemic Heart Failure Trial (TAC-HFT) is directly comparing human MSCs and human BMMNCs in a prospective manner. The recently published preliminary data from the phase I pilot study of TAC-HFT suggest that transendocardial injection of autologous bone marrow progenitor cells (human MSCs or human BMMNCs) improves regional contractility in a myocardial scar and reverse LV remodeling.

Because of the absence of major histocompatibility complex class II, MSCs are immunoprivileged and suppress T-cell proliferation. These cells are being evaluated in the POSEIDON in Dilated Cardiomyopathy (POSEIDON-DCM), which is comparing allogeneic MSCs with autologous MSCs in patients with nonischemic dilated cardiomyopathy. In the early stage study of patients with ischemic cardiomyopathy, POSEIDON demonstrated that transendocardial injection of allogeneic and autologous MSCs favorably affected patient functional capacity, quality of life, and ventricular remodeling. Cardio3 BioSciences is currently recruiting patients in its phase III trial (Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure [CHART-1]) to examine autologous bone marrow–derived mesenchymal cardiopoietic cells (C3BS-CQR-1) in patients with chronic HF. In this study, the investigators are using a unique cardiopoietic cocktail of growth factors (transforming growth factor-β1, bone morphogenetic protein-4, activin A, retinoic acid, insulin-like growth factor-1, fibroblast growth factor-2, α-thrombin, and interleukin-6), which has been reported to engage MSCs to differentiate into CSCs. Using a patient-specific multicellular therapy expanded from a small sample of a patient’s own bone marrow, Aastrom Biosciences is using Ixmyelocel-T (primarily CD90+ MSCs, CD14+ monocytes, and alternatively activated macrophages) to evaluate the efficacy, safety, and tolerability of transendocardial injection in subjects with HF because of ischemic dilated cardiomyopathy. The Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients with Dilated Cardiomyopathy (NOGA-DCM) study is using CD34+ cells in patients with HF. This study is being performed by Dr Vrtovec’s group, who has recently demonstrated that intracoronary stem cell transplantation is associated with improved ventricular function, exercise tolerance, and long-term survival (≤5 years) in patients with dilated cardiomyopathy. NOGA-DCM is designed to directly compare the effects of intracoronary and intramyocardial stem cell delivery in nonischemic dilated cardiomyopathy at 1-year follow-up. Aside from these studies using bone marrow–derived cells, Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR), sponsored by Capricor Inc, is a phase I/II study that tests the safety and efficacy of intracoronary delivery of allogeneic CDCs in patients with an anterior MI and HF.

Conclusions
When considering the current status of cell-based therapies for HF, it is important to keep a historical perspective. We are still at the dawn of the era of regenerative medicine. Only 15 years ago suggesting that it was possible to regenerate dead myocardium would have been considered science fiction. Notwithstanding the many mechanistic, pathophysiological, and practical issues that remain unresolved, it is important to remember that tremendous progress has been made in a relatively short time. Many promising candidates for cell therapy have been identified, both in experimental animals and in humans, and several studies are ongoing in patients with chronic HF (Figure 1; Tables 1–3). Never has an idea been translated from preclinical models to humans so quickly. Importantly, cell therapy appears to be safe, to date, no adverse effect of stem/progenitor cells has been reported.

It is true that the precise mechanism of action of stem cells remains unclear, and their efficacy in HF has not been proven. But wouldn’t it be surprising if a conclusive answer to these complex questions had been achieved in just a decade? How long did it take for reperfusion therapy to become a routine part of the management of acute MI? And do we understand the mechanism of action of all therapies that we use daily? We must not succumb to irrational impatience or premature nihilism. When a novel therapy comes along, the clinical trials performed in the first few years are generally small and inconclusive. This has indeed been the case for stem cells in HF; nevertheless, the results are encouraging, and the therapy appears safe. What is important now is (1) to resolve issues concerning optimal cell type, dosage, and route and timing of administration, and (2) to proceed with rigorous, large-scale, rationally designed, randomized clinical trials. With this approach, we believe that cell-based therapies are likely to become a clinical reality that may revolutionize the management of HF.

Acknowledgments
We gratefully acknowledge Heather L. Jones for expert assistance with graphics design.

Sources of Funding
The work discussed in this article was supported in part by the National Institutes of Health grants R01-HL-68088, HL-70897, HL-76794, HL-78825, HL-55757, HL-74351, and HL-91202.
Disclosures
None.

References


Stem Cells
human embryonic stem cells expressing a “suicide” gene.

Differentiation of human embryonic stem cells and induced pluripotent stem cells can differentiate into myocytes with structural and functional properties.


Differentiation of embryonic stem cell-derived neural precursors averts tumor formation after transplantation.


Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts.

Stem Cells 2006;126:663–676.


BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHF Registry. Circ Res. 2007;100:1234–1241.


Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo.

Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo.


Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs E, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004;94:678–685.


Gnecci M, He H, Liang OD, Melo LG, Morello F, Mu H, Noizeux N, Zang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367–368.


Cell Therapy for Heart Failure: A Comprehensive Overview of Experimental and Clinical Studies, Current Challenges, and Future Directions
Santosh K. Sanganalmath and Roberto Bolli

Circ Res. 2013;113:810-834
doi: 10.1161/CIRCRESAHA.113.300219

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/113/6/810

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/